Sharon Bio-Medicine Ltd has informed BSE that the company's formulation plant at Dehradun has been reapproved by UK Medicines & Health Care Product Regulatory Agency (MHRA) authorities for complying with principles and other guidelines of good manufacturing practices (GMP) for tablets and capsules. This will further increase sales to Europe and other regulated countries except USA in near future.
Top Section
Explore Business Standard